iPSC-Derived B Cell Lineages for Scalable Cell Therapy Supply
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical use of B cell lineages for cell therapy is limited by the small numbers of such cells that can be isolated from regular leukapheresis products, necessitating the development of large-scale, off-the-shelf B lymphocyte lineages to combat cancer and infectious diseases.
Innovation Solution
A method for generating hematopoietic lineages, including B cells, from human induced pluripotent stem cells (iPSCs) through ex vivo processes, involving differentiation to embryoid bodies, CD34+ enrichment, endothelial-to-hematopoietic transition, and gene editing to address HLA matching issues, enabling the production of functional B cell lineages and their progenitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If B cells are isolated from regular leukapheresis products, then the cells can be obtained through conventional methods, but the numbers of such cells are limited and insufficient for clinical therapy
Solution Approach 1:
The patent applies preliminary action by pre-differentiating pluripotent stem cells into B cell lineages ex vivo before clinical administration. This allows large numbers of functional B cells to be generated in advance through controlled differentiation protocols, eliminating the limitation of obtaining only small numbers of B cells from leukapheresis products.
Solution Approach 2:
The patent uses pluripotent stem cells as a renewable source to copy and generate large numbers of B cells. By differentiating stem cells into B cell lineages, the system creates a scalable production method that can generate sufficient cell numbers for therapy, unlike the limited harvesting from leukapheresis.
2Productivity
If large scale B cell production is achieved through stem cell differentiation, then sufficient cell numbers are obtained, but the process complexity increases significantly
Solution Approach 1:
The patent segments the complex differentiation process into distinct sequential stages: pluripotent stem cell preparation, embryoid body formation, hematopoietic progenitor generation, and B cell lineage differentiation. Each stage uses specific culture conditions and cytokine cocktails, making the overall complex process manageable and scalable through standardized protocols.
Solution Approach 2:
The patent systematically changes cultural parameters at each differentiation stage, including cytokine concentrations, culture medium composition, and physical conditions, to guide stem cells through the differentiation hierarchy. This controlled parameter adjustment enables scalable production while maintaining process control despite increasing complexity.
3Reliability
If gene editing is performed on iPSCs to address HLA matching, then histocompatibility issues are improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent performs gene editing on pluripotent stem cells at the earliest stage, before differentiation. This preliminary genetic modification ensures that all subsequently differentiated B cells inherit the desired HLA characteristics, achieving consistent histocompatibility without requiring post-differentiation editing of each individual cell.
Solution Approach 2:
The patent creates universal donor B cells by editing pluripotent stem cells to have reduced or modified HLA expression. These edited stem cells can then differentiate into B cells suitable for multiple recipients, making the gene editing investment beneficial for multiple therapeutic applications rather than a single-cell limitation.
Data Source
AI summary
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or lymphoid organs. The present invention in some aspects provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.